Intra-Cellular Therapies Inc. (ITCI) Major Shareholder Alafi Capital Co Llc Buys 258,065 Shares
Intra-Cellular Therapies Inc. (NASDAQ:ITCI) major shareholder Alafi Capital Co Llc acquired 258,065 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were bought at an average cost of $15.50 per share, for a total transaction of $4,000,007.50. Following the completion of the transaction, the insider now directly owns 3,953,270 shares of the company’s stock, valued at approximately $61,275,685. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Intra-Cellular Therapies Inc. (NASDAQ ITCI) traded up 2.64% during mid-day trading on Tuesday, reaching $15.92. 1,013,501 shares of the company’s stock were exchanged. Intra-Cellular Therapies Inc. has a 52-week low of $7.85 and a 52-week high of $22.67. The company’s market cap is $691.31 million. The stock has a 50-day moving average price of $17.16 and a 200 day moving average price of $13.34.
Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.74) by $0.33. Intra-Cellular Therapies had a negative return on equity of 27.92% and a negative net margin of 32,834.94%. The business had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.03 million. During the same period last year, the company earned ($0.71) earnings per share. Intra-Cellular Therapies’s quarterly revenue was down 52.2% on a year-over-year basis. Equities analysts predict that Intra-Cellular Therapies Inc. will post ($2.36) earnings per share for the current fiscal year.
ITCI has been the subject of a number of research analyst reports. BidaskClub downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research report on Friday, July 28th. Cantor Fitzgerald reissued a “buy” rating on shares of Intra-Cellular Therapies in a research note on Wednesday, August 9th. Piper Jaffray Companies set a $10.00 price target on shares of Intra-Cellular Therapies and gave the company a “hold” rating in a report on Thursday, August 10th. Zacks Investment Research upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Tuesday, August 15th. Finally, Leerink Swann reaffirmed a “market perform” rating and issued a $12.00 price target on shares of Intra-Cellular Therapies in a research note on Tuesday, August 15th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $24.38.
Large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new position in shares of Intra-Cellular Therapies during the 2nd quarter worth approximately $103,000. Bank of America Corp DE raised its holdings in shares of Intra-Cellular Therapies by 53.4% in the first quarter. Bank of America Corp DE now owns 9,660 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 3,363 shares during the last quarter. Fred Alger Management Inc. acquired a new stake in shares of Intra-Cellular Therapies in the second quarter valued at approximately $161,000. Voya Investment Management LLC raised its holdings in shares of Intra-Cellular Therapies by 16.0% in the second quarter. Voya Investment Management LLC now owns 16,911 shares of the biopharmaceutical company’s stock valued at $210,000 after purchasing an additional 2,338 shares during the last quarter. Finally, Citigroup Inc. raised its holdings in shares of Intra-Cellular Therapies by 32.8% in the second quarter. Citigroup Inc. now owns 17,395 shares of the biopharmaceutical company’s stock valued at $216,000 after purchasing an additional 4,295 shares during the last quarter. 71.79% of the stock is owned by hedge funds and other institutional investors.
Intra-Cellular Therapies Company Profile
ITI Inc is a United States-based company. The Company is a subsidiary of Intra-Cellular Therapies Inc
Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.